Characteristics of subjects with schizophrenia spectrum disorder with and without antipsychotic medication – A 10-year follow-up of the Northern Finland 1966 Birth Cohort study - 15/01/13
, M. Haapea a, b, c, 1, J. Miettunen a, d, 2, E. Jääskeläinen a, 3, J. Veijola a, 4, M. Isohanni a, 5, H. Koponen e, 6
Corresponding author. Tel.: +358 44 0690706; fax: +358 8 336169.Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
| pages | 6 |
| Iconographies | 0 |
| Vidéos | 0 |
| Autres | 0 |
Abstract |
Objective |
To estimate the prevalence of non-medicated subjects having schizophrenia spectrum disorder and to study how they differ from medicated subjects in terms of sociodemographic and illness-related variables. We also aim to find the predictors for successful antipsychotic withdrawal.
Methods |
Data of 70 subjects with schizophrenic psychoses (mean duration of illness 10.4 years) from the Northern Finland 1966 Birth Cohort were gathered by interview at the age of 34 and from hospital records. The stability of remission was assessed by comparing hospitalization rates between non-medicated and medicated subjects over an 8.7-year additional follow-up period.
Results |
Twenty-four (34%) subjects were currently not receiving medication. They were more often males, less often on a disability pension, more often in remission, and had better clinical outcomes. Relapses during the follow-up were equally frequent between non-medicated and medicated subjects (47% vs. 56%). Not having been hospitalised during previous 5 years before the interview predicted long-term successful antipsychotic withdrawal without relapse.
Conclusions |
Despite a lack of precise predictors, there might be subgroup of schizophrenia spectrum subjects who do not need permanent antipsychotic medication, and a fewer previous psychiatric treatments may indicate such a subgroup.
Le texte complet de cet article est disponible en PDF.Keywords : Antipsychotics, Medicated, Non-medicated, Remission, Schizophrenia
Plan
Vol 28 - N° 1
P. 53-58 - janvier 2013 Retour au numéro
Article précédent
- Oral disease in relation to future risk of dementia and cognitive decline: Prospective cohort study based on the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified-Release Controlled Evaluation (ADVANCE) trial
- G.-D. Batty, Q. Li, R. Huxley, S. Zoungas, B.-A. Taylor, B. Neal, B. de Galan, M. Woodward, S.-B. Harrap, S. Colagiuri, A. Patel, J. Chalmers, On behalf of the ADVANCE Collaborative group
- Socio-economic disadvantage and delusional-like experiences: A nationwide population-based study
- S. Saha, J.G. Scott, D. Varghese, J.J. McGrath
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’achat d’article à l’unité est indisponible à l’heure actuelle.
Déjà abonné à cette revue ?